Compare Sana Biotechnology Inc (SANA) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Schlumberger NV — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Schlumberger NV trades at $46.77 (market cap $69.36B). The key difference: Schlumberger NV is far larger — about 79.4× Sana Biotechnology Inc's market cap, and Schlumberger NV pays a 2.54% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SLB | |
|---|---|---|
Market Cap | $873.84M | $69.36B |
Sector | Health | Energy |
52-Week High | $5.92 | $58.01 |
52-Week Low | $2.68 | $31.72 |
Enterprise Value | $848.03M | $77.58B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SLB trades at $46.59, down 0.85% on the day, with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with a 9.26% net margin and 14.57% ROE, supported by $6.5B in operating cash flow. Recent strategic moves include a partnership with Liberty Energy for data center power solutions and major contract wins like the Baleine Phase 3 EPC award, positioning SLB to capitalize on energy and AI infrastructure demand.
The outlook is cautiously optimistic with an 84.85% analyst buy rating and a $62.83 consensus price target implying 35% upside. Risks include oil price volatility and execution challenges in new ventures, but SLB's solid balance sheet and digital growth initiatives offer a compelling case for long-term investors amid near-term market weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
